0001209191-18-003648.txt : 20180116
0001209191-18-003648.hdr.sgml : 20180116
20180116172941
ACCESSION NUMBER: 0001209191-18-003648
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180111
FILED AS OF DATE: 20180116
DATE AS OF CHANGE: 20180116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walker Luke Nathaniel
CENTRAL INDEX KEY: 0001701440
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33882
FILM NUMBER: 18529381
MAIL ADDRESS:
STREET 1: C/O CASCADIAN THERAPEUTICS, INC.
STREET 2: 2601 4TH AVE., SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001412067
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 260868560
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2601 FOURTH AVENUE
STREET 2: SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: (206) 801-2100
MAIL ADDRESS:
STREET 1: 2601 FOURTH AVENUE
STREET 2: SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: Oncothyreon Inc.
DATE OF NAME CHANGE: 20070927
FORMER COMPANY:
FORMER CONFORMED NAME: Biomira CORP
DATE OF NAME CHANGE: 20070911
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-11
0
0001412067
Cascadian Therapeutics, Inc.
CASC
0001701440
Walker Luke Nathaniel
C/O CASCADIAN THERAPEUTICS, INC.
3101 WESTERN AVE., SUITE 600
SEATTLE
WA
98121
0
1
0
0
SVP, Clinical Development
Common Stock
2018-01-11
4
M
0
1950
0.00
A
5940
D
Common Stock
2018-01-11
4
F
0
637
3.92
D
5303
D
Restricted Share Unit (RSU)
2018-01-11
4
M
0
1950
0.00
D
2027-01-11
Common Stock
1950
5850
D
637 shares of the restricted share unit ("RSU") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person.
Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs.
Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date.
/s/ Julia M. Eastland as attorney-in-fact for Luke N. Walker
2018-01-16